James L. Mohler, MD
(approved or under study)
|Given in combination with prednisone to patients with mCRPC who have received prior docetaxel||Inhibits CYP17 enzyme activity||Janssen Biotech (Johnson & Johnson)||FDA approved April 2011|
|mCRPC who have previously received docetaxel||Inhibits androgen binding to ARs, AR nuclear translocation and interaction with DNA||Medivation/ Astellas Pharma||FDA approved August 2012|
|Chemotherapy-naïve CRPC||Inhibits CYP17 lyase, antagonizes testosterone binding to AR, degrades AR protein||Tokai Pharmaceuticals||8-arm ARMOR1 dose-escalation study completed (NCT00959959); phase II study planned|
|mCRPC, chemotherapy-naïve mCRPC||Acts as nonsteroidal, selective CYP17 lyase inhibitor||Millennium/Takeda||Separate phase III studies evaluating orteronel plus prednisone (NCT01193257, NCT01193244)|
|High-risk patients, defined by Gleason score and PSA; no distant metastases within 90 days||Radiation Therapy Oncology Group/ National Cancer Institute||Phase III study evaluating orteronel plus radiation and hormonal therapy (NCT01546987)|
|Recurrent prostate cancer after castration||Acts as pan-HDAC inhibitor||Novartis/ New York University School of Medicine||Phase I/II combination study with bicalutamide (NCT00878436)|
|Vorinostata||Given with androgen-deprivation therapy before radical prostatectomy to patients with localized prostate cancer||HDAC inhibitor||National Cancer Institute||Phase II combination study in patients with stages I-III cancer (NCT00589472)|
aVorinostat is approved under the name Zolinza for the treatment of cutaneous T-cell lymphoma.
CYP17 indicates 17 α-hydroxylase/C17,20-lyase; HDAC, histone deacetylase; mCRPC, metastatic castration-resistant prostate cancer; PSA, prostate-specific antigen.
|Title||Expiration Date||CME Credits|
|Clinical Vignette Series: 33rd Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®||Feb 19, 2017||3.0|
|Community Practice Connections™: New York GU™: 9th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies||May 27, 2017||1.5|